Figure 6.

HLA class I and HLA-DR antigen expression in advanced pediatric solid tumors. The percentages of specimens with HLA class I (A, B) and HLA-DR (C, D) immunoreactivity on tumor cells assessed by IHC were scored using a semi-quantitative scale as follows: 3 (“high”, ≥ 70% tumor cells), 2 (“intermediate”, ≥ 30 to < 70%), 1 (“low”, ≥ 5 to < 30%), and 0 (negative, < 5%). Tumor samples are classified by specific tumor types (A, C), or subtypes for RMS (eRMS, aRMS), neuroblastoma (MYCN-NA, MYCN-A, 11qWT, 11qLOH), and HGG (GBM, non-GBM) (B, D). The numbers of samples are indicated below the corresponding bar charts.